Tdi-11861 (a fast-acting male contraceptive) approved for human clinical trials by the end of 2026?
Gezondheid en geneeskundeOne-Off2mnd
FutuurBeschikbaarheid controlerenGeverifieerde afwikkelingsgegevensHuidige impliciete kans
Nee 93%
Nee 93%Marktkwaliteit
31 / 100
Lage kwaliteit24u volume
—
Liquiditeit
€ 249,5
Lage liquiditeitHandelaren
10
Reacties
0
Marktdata
Bijgewerkt 1 minuut geleden
Trends
Regels
Researchers Jochen Buck and Lonny Levin of Weill Cornell Medicine have discovered a fast-acting and temporary male contraceptive called tdi-11861.
- This substance, a soluble adenylyl cyclase (sac) inhibitor, works by stopping sperm from swimming, rendering the subject temporarily infertile.
- According to initial studies in mice, it takes effect within half an hour, and fertility returns within a day.
- However, despite the encouraging results in mice, more animal tests and human trials are required before it can be confirmed as a breakthrough in male contraception.
- This prediction market aims to determine whether tdi-11861 will be approved for human clinical trials before or on December 31, 2026.
- The outcome will be determined based on an official announcement from the relevant regulatory bodies or agencies, such as the FDA, or news reports from major news outlets that Futuur deems credible.
